In another study with 38 patients who underwent [177Lu]Lu-PSMA-617 radioligand therapy (RLT), the change in total tumor volume before and after RLT was significantly associated with PSA response and overall survival after a median follow-up of 17 months [19]. This evidence concerns the gene FOLH1 and neoplasm.